WASHINGTON — US regulators on Tuesday approved Kalydeco, a new, gene-targeted drug treatment for people who have a rare kind of the incurable lung disease cystic fibrosis. Made by the Massachusetts-based Vertex Pharmaceuticals, Kalydeco...